Biomarkers Products & Reviews

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S1) is a recombinant antigen which contains the Spike protein amino acids 1-674. Spike S1 protein is manufactured in HEK293 mammalian cells, ensuring the most authentic post-translational modifications.

Novel Coronavirus 2019-nCoV (SARS-CoV-2) Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike S2 protein, amino acids 685-1211. Spike S2 is manufactured in mammalian HEK293 cells to ensure the most authentic post-translational modifications.

The Native Antigen Company offers a selection of complementary easy-to-use antibody conjugation formats, with a wide range of labels suitable for use in most applications. On request we can also undertake custom conjugation of proteins and antibodies.

With decades of experience in the field of native antigen and recombinant protein production, and assay development, The Native Antigen Company is able to undertake a wide range of custom projects on your behalf.  

SARS-CoV-2 Nucleoprotein is a recombinant antigen manufactured in E. coli cells to high purity for use in vaccine research and immunoassay development. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Spike Glycoprotein (S2) is a recombinant antigen which contains the Spike protein amino acids 685-1211 of subunit 2. Spike S2 protein is manufactured to high yield and purity using the Native Antigens baculovirus-insect cell platform. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

SARS-CoV-2 Spike-E-M Mosaic protein is a recombinant antigen manufactured in E. coli with greater than 95% purity, and containing the Spike (S), Envelope (E) and Membrane (M) immunodominant regions. SARS-CoV-2, previously known as the 2019 Novel Coronavirus (2019-nCoV), causes the pandemic COVID-19 disease.

Human Coronavirus 229E Nucleoprotein is a recombinant protein containing 359 amino acids derived from the nucleocapsid sequence, with a C-terminal 6xHis tag. It is manufactured in E. coli with greater than 95% purity.

Human Coronavirus NL63 Nucleoprotein is a recombinant protein containing the nucleocapsid C-terminal region (130 amino acids), cloned and expressed in E. coli, and purified by affinity chromatography (nickel column) with greater than 95% purity.

ProteaseMax™ Surfactant is a high-quality reagent for use in protein and peptide sample preparation.   ProteaseMax™ Surfactant solubilizes proteins and ensures fast and improved protein digestion with trypsin or chymotrypsin. It is designed to degrade over the course of a digestion reaction, yielding products that are compatible with downstream methods such as mass spectrometry (MS) and liquid chromatography (LC). For…

Unleash the full power of a well-designed library. With Twist Bioscience, you are assured that the library you design contains the specific modifications, exactly where you want them, saving you valuable resources for the downstream screening process.

Twist Biopharma, a division of Twist Bioscience, provides services to help accelerate the way our partners discover and optimize antibody therapeutics with our unique DNA writing technology. Twist constructs proprietary antibody libraries precisely designed to match sequences that occur in the human body giving our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

Twist Biopharma, a division of Twist Bioscience, provides services to help accelerate the way our partners discover and optimize antibody therapeutics with our unique DNA writing technology. Twist constructs proprietary antibody libraries precisely designed to match sequences that occur in the human body giving our partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

BioIVT has the expertise in the processes required for ethical acquisition of biospecimens that cover a wide range of disease states and the protocols needed to produce reliable data. With over 425 IRB-approved clinical sites, BioIVT provides clinical specimens for nearly all disease states.

BioIVT supplies high quality, ready to ship or custom plasma, serum, and whole blood—both normal and disease-state—collected from a diverse pool of consented donors under IRB-approved protocols or a wide variety of species.

As the world's largest private repository of human cerebrospinal fluid, BioIVT’s Center for NeuroExcellence offers 35,000+ healthy and 113,000+ diseased donor samples allowing for comparative studies and precise control matching. The samples are ethically collected following strict quality standards and feature detailed clinical data and matching blood, plasma, or sera.

Accelerating radiopharmaceutical development in oncology

Proteins purified from their natural, endogenous sources, preserving post-translational modifications and complex native structures for biologically relevant research applications.